The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial.

doi:10.1158/1055-9965.EPI-07-0658

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology - 1 Feb 2008

Simoneau Anne R, Gerner Eugene W, Nagle Ray, Ziogas Argyrios, Fujikawa-Brooks Sharon, Yerushalmi Hagit, Ahlering Thomas E, Lieberman Ronald, McLaren Christine E, Anton-Culver Hoda, Meyskens Frank L

Abstract excerpt

BACKGROUND: Prostate cancer is a major health issue, and prevention of prostate cancer and/or its progression will yield benefits for men. Difluoromethylornithine (DFMO) is an antiproliferative agent, inhibiting ornithine decarboxylase, the first enzyme in the polyamine pathway, and has been studied as a therapeutic and chemopreventive agent. The prostate has high levels of tissue polyamines and has shown...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Biopsy

Share to Polyamines

Share to Prostate

Share to Prostate-Specific Antigen

Share to Prostatic Neoplasms

Share to Statistics, Nonparametric

Source

Open in PubMed Open full text

Identifiers

PMID: 18268112
DOI: 10.1158/1055-9965.EPI-07-0658
PMCID: PMC2515594

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial.PMID 18268112Read ↗

Phthalate exposure induces microRNA-5010/Nrf2-EGR1/GDF15 signaling expression in prostate cancerSemantic proximity Read ↗

Recent advances in treatment for Benign Prostatic HyperplasiaSemantic proximity Read ↗

Prevention of prostate cancer.Semantic proximity Read ↗

Associations between variants in the cyclooxygenase 2 enzyme gene (PTGS2) and development of benign prostate enlargement.Semantic proximity Read ↗

Gastrointestinal and Genitourinary Toxicity Profiles of Metformin Versus Placebo in Men With Prostate Cancer Receiving Pelvic Radiotherapy: Interim Toxicity Results of a Double-blinded, Multicenter, Phase II Randomized Controlled TrialSemantic proximity Read ↗

Comparative Study of the Efficacy and Safety of Plasmakinetic Enucleation of the Prostate in Different Stages Versus Plasmakinetic Resection of the Prostate for Benign Prostate HyperplasiaSemantic proximity Read ↗

Modulation of biologic endpoints by topical difluoromethylornithine (DFMO), in subjects at high-risk for nonmelanoma skin cancer.Semantic proximity Read ↗

A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer.Semantic proximity Read ↗

Hormonal prevention of prostate cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.